Erratum : Optometry and Vision Science

Secondary Logo

Journal Logo

ERRATA

Erratum

doi: 10.1097/OPX.0000000000001935
  • Free

The authors of the articles listed below report the following errors:

CITT-ART Investigator Group. Treatment of Symptomatic Convergence Insufficiency in Children Enrolled in the Convergence Insufficiency Treatment Trial – Attention & Reading Trial: A Randomized Clinical Trial. Optom Vis Sci 2019;96(11):825–835.

CITT-ART Investigator Group. Effect of Vergence/Accommodative Therapy on Reading in Children with Convergence Insufficiency: A Randomized Clinical Trial. Optom Vis Sci 2019;96(11):836–849.

CITT-ART Investigator Group. Effect of Vergence/Accommodative Therapy on Attention in Children with Convergence Insufficiency: A Randomized Clinical Trial. Optom Vis Sci 2021;98(3):222–233.

The total sample size for the analyses in the above articles incorrectly included 10 (3.2%) children who were randomized to therapy but retrospectively determined to be ineligible (6 of 206 randomized to the vergence/accommodative therapy group and 4 of 104 assigned to placebo therapy). All 10 failed to meet the single eligibility criterion of “insufficient positive fusional vergence.”. Each child completed the 16-week primary outcome evaluation. Sensitivity analyses, as reported in the following tables, showed little to no impact of exclusion on the previously published findings.

Portion of Table 5 from Effect of Vergence/Accommodative Therapy on Reading in Children with Convergence Insufficiency: A Randomized Clinical Trial. (Optom Vis Sci 2019;96(11):836–849).

Treatment difference*,† estimates for measures of reading

-
Reading outcome All participants Excluding ineligible
Mean (95% CI) Effect size Mean (95% CI) Effect size
Wechsler Individual Achievement Test, 3rd edition (Standard Score)
Reading Comprehension −0.12
(−1.89 to 1.66)
−0.02 −0.33
(−2.13 to 1.48)
−0.05
Word Reading −0.94
(−2.16 to 0.28)
−0.19 −0.89
(−2.13 to 0.35)
−0.18
Pseudoword Decoding 0.33
(−1.00 to 1.66)
0.06 0.50
(−0.87 to 1.86)
0.09
Oral Reading Fluency 0.051
(−1.11 to 1.21)
0.01 0.13
(−1.04 to 1.30)
0.03
Listening Comprehension −1.23
(−3.33 to 0.87)
−0.14 −1.44
(−3.59 to 0.70)
−0.17
Gates-MacGinitie Reading Tests, 4th edition (Normal Curve Equivalent score)
Reading Comprehension 0.31
(−2.83 to 3.45)
0.02 0.67
(−2.55 to 3.89)
0.05
AIMSweb Curriculum-based Measures (Z-score)
R-CBM Oral Reading Fluency −0.022
(−0.11 to 0.071)
−0.06 −0.036
(−0.13 to 0.059)
−0.09
Maze 0.026
(−0.13 to 0.18)
0.04 0.034
(−0.12 to 0.19)
0.05
*Calculated as adjusted mean for the vergence/accommodative therapy group minus the adjusted mean for the placebo therapy group. †Adjusted for baseline reading scores along with any other identified covariates.

 Table 4 from Treatment of Symptomatic Convergence Insufficiency in Children Enrolled in the Convergence Insufficiency Treatment Trial – Attention & Reading Trial: A Randomized Clinical Trial. (Optom Vis Sci 2019;96(11):825–835).

Mean change (95% confidence interval) in outcome measures at 16 weeks by treatment group

-
All participants Excluding ineligible
Measure Vergence/ accommodative therapy Placebo therapy Vergence/ accommodative therapy Placebo therapy
Near point of convergence break (cm)
 Baseline* 14.0
(12.9 to 15.1)
14.9
(13.3 to 16.5)
14.2
(13.0 to 15.3)
15.0
(13.4 to 16.6)
 Week 16, unadjusted 3.9
(3.5 to 4.4)
8.3
(7.2 to 9.5)
4.0
(3.5 to 4.4)
8.5
(7.3 to 9.7)
 Change from baseline to 16-week outcome, adjusted −10.4
(−11.3 to −9.6)
−6.2
(−7.2 to −5.2)
−10.6
(−11.4 to −9.7)
−6.2
(−7.2 to −5.2)
Positive fusional vergence blur or break (Δ) at near
 Baseline* 11.5
(10.9 to 12.1)
11.3
(10.5 to 12.1)
11.4
(10.8 to 12.1)
11.3
(10.4 to 12.1)
 Week 16, unadjusted 34.5
(33 to 36)
20.0
(18.3 to 21.8)
34.4
(32.9 to 36.0)
20.1
(18.3 to 21.9)
 Change from baseline to 16-week outcome, adjusted§ 23.2
(20.8 to 25.6)
8.8
(6.1 to 11.5)
23.2
(20.8 to 25.6)
8.9
(6.2 to 11.6)
CISS score
 Baseline* 28.9
(27.7 to 30.1)
30.4
(28.7 to 32.1)
28.9
(27.7 to 30.1)
30.2
(28.5 to 32.0)
 Week 16, unadjusted 17.8
(16.3 to 19.3)
20.0
(17.8 to 22.3)
17.9
(16.4 to 19.4)
19.7
(17.5 to 21.9)
 Change from baseline to 16-week outcome, adjusted −11.8
(−13.4 to −10.3)
−10.4
(−12.4 to −8.4)
−11.6
(−13.2 to −9.9)
−10.5
(−12.5 to −8.4)
*Baseline values for participants who completed 16-week outcome. †Adjusted for baseline near point of convergence and the interaction of baseline near point of convergence with treatment group. ‡The blur finding was used, but if blur was not reported, the break finding was used. §Adjusted for baseline positive fusional vergence. ¶Adjusted for parent-reported attention-deficit/hyperactivity disorder, baseline accommodative amplitude, baseline accommodative facility, and baseline CISS score. CISS = Convergence Insufficiency Symptom Survey.

Portion of Tables 5 & 6 from CITT-ART Investigator Group. Effect of Vergence/Accommodative Therapy on Attention in Children with Convergence Insufficiency: A Randomized Clinical Trial. (Optom Vis Sci 2021;98(3):222–233).

Cohen’s d and 95% confidence interval (CI) for between group difference in each measure of attention using all participants and excluding those ineligible

-
All participants Excluding ineligible
Measure Cohen’s d 95% CI Cohen’s d 95% CI
Strengths and Weaknesses of ADHD Symptoms and Normal Behavior Rating Scale (SWAN)
Inattentive, parent report* −0.036 −0.28 to 0.21 −0.010 −0.26 to 0.24
Hyperactivity, parent report 0.003 −0.24 to 0.24 0.030 −0.21 to 0.27
Inattentive, teacher report −0.102 −0.39 to 0.19 −0.131 −0.43 to 0.17
Hyperactivity, parent-report 0.032 −0.26 to 0.32 −0.003 −0.30 to 0.29
Swanson, Nolan, and Pelham IV (SNAP) score
Inattentive, parent report −0.083 −0.33 to 0.17 −0.082 −0.34 to 0.17
Hyperactivity, parent report 0.071 −0.17 to 0.31 0.067 −0.18 to 0.31
Homework Problems Checklist
Total score No ADHD medication use 0.085 −0.16 to 0.33 0.083 −0.17 to 0.34
ADHD medication use 0.88 0.043 to 1.67 0.60 −0.25 to 1.41
Inattention/Avoidance of homework 0.095 −0.14 to 0.33 0.078 −0.17 to 0.32
Poor productivity/ non-adherence with homework rules No ADHD medication use 0.087 −0.16 to 0.34 0.088 −0.17 to 0.34
ADHD medication use 0.97 0.12 to 1.76 0.77 −0.10 to 1.58
d2 Test of Attention
Total number attempted −0.14 −0.38 to 0.10 −0.094 −0.34 to 0.15
Total number correct −0.20 −0.44 to 0.041 −0.18 −0.42 to 0.065
Concentration Performance −0.13 −0.37 to 0.11 −0.13 −0.38 to 0.12
‡Calculated as week 16 outcome of placebo therapy minus V-A therapy divided by common standard error.

Copyright © 2022 American Academy of Optometry